Want to see IN:GLENMARK full AI Analyst Report?
GLENMARK Stock Chart & Stats
₹2065.95
-₹29.45(-1.81%)
At close: 4:00 PM EST
₹2065.95
-₹29.45(-1.81%)
Day’s Range― - ―
52-Week Range₹1,800.00 - ₹2,536.85
Previous CloseN/A
Volume301.32K
Average Volume (3M)18.21K
Market Cap
₹658.43B
Enterprise Value₹596.10B
Total Cash (Recent Filing)₹11.76B
Total Debt (Recent Filing)₹5.94B
Price to Earnings (P/E)36.7
Beta0.54
Next Earnings
Nov 05, 2026EPS Estimate
15.6Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)48.26
Shares Outstanding282,224,670
10 Day Avg. Volume12,656
30 Day Avg. Volume18,212
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.72
Price to Sales (P/S)3.54
P/FCF Ratio30.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)80.9
Revenue Forecast (FY)₹167.99B
Bulls Say, Bears Say
Bulls Say
Revenue And Profit RecoverySteady revenue expansion indicates improving scale across Glenmark’s formulations and API businesses, while the FY2026 margin recovery shows stronger earnings conversion. If maintained, this combination can support reinvestment, strengthen operating resilience, and improve profitability over the next several quarters.
Lower Financial LeverageThe sharp reduction in leverage materially lowers financial risk and gives Glenmark greater flexibility to fund products, operations, and other strategic priorities. A more conservatively positioned balance sheet also reduces pressure from financing costs and improves resilience if operating conditions become less favorable.
Strong Latest-Year Cash GenerationStrong positive operating and free cash flow in FY2026 provides evidence that the earnings recovery is translating into cash rather than remaining purely accounting-based. This supports internal funding of capital needs, debt management, and continued investment without relying as heavily on external financing.
Bears Say
Earnings VolatilityThe swing from profit to a large FY2024 loss and then back to profit shows that Glenmark’s earnings profile has not yet demonstrated consistent stability. Such volatility can make future profitability harder to forecast and may limit confidence that the latest margin improvement will persist across business cycles.
Inconsistent Cash-Flow HistoryNegative operating and free cash flow in the two years before FY2026 indicates that cash conversion has been unreliable over the recent period. Even with the latest recovery, this history raises concern that reported earnings may not consistently translate into funds available for investment, debt reduction, or shareholder returns.
Declining FY2026 Free Cash FlowThe year-over-year decline in FY2026 free cash flow tempers the otherwise strong cash-generation picture and suggests that the recovery did not translate into continually expanding financial flexibility. Sustained cash-flow growth will be important for supporting investment and demonstrating that improvement is durable rather than uneven.
Glenmark Pharmaceuticals Limited News
GLENMARK FAQ
What was Glenmark Pharmaceuticals Limited’s price range in the past 12 months?
Glenmark Pharmaceuticals Limited lowest stock price was ₹1800.00 and its highest was ₹2536.85 in the past 12 months.
What is Glenmark Pharmaceuticals Limited’s market cap?
Glenmark Pharmaceuticals Limited’s market cap is ₹658.43B.
When is Glenmark Pharmaceuticals Limited’s upcoming earnings report date?
Glenmark Pharmaceuticals Limited’s upcoming earnings report date is Nov 05, 2026 which is in 5 days.
How were Glenmark Pharmaceuticals Limited’s earnings last quarter?
Glenmark Pharmaceuticals Limited released its earnings results on Jul 31, 2026. The company reported ₹17.11 earnings per share for the quarter, missing the consensus estimate of ₹17.3 by -₹0.19.
Is Glenmark Pharmaceuticals Limited overvalued?
According to Wall Street analysts Glenmark Pharmaceuticals Limited’s price is currently Overvalued.
Does Glenmark Pharmaceuticals Limited pay dividends?
Glenmark Pharmaceuticals Limited pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 0.22%. See more information on Glenmark Pharmaceuticals Limited dividends here
What is Glenmark Pharmaceuticals Limited’s EPS estimate?
Glenmark Pharmaceuticals Limited’s EPS estimate is 15.6.
How many shares outstanding does Glenmark Pharmaceuticals Limited have?
Glenmark Pharmaceuticals Limited has 282,224,670 shares outstanding.
What happened to Glenmark Pharmaceuticals Limited’s price movement after its last earnings report?
Glenmark Pharmaceuticals Limited reported an EPS of ₹17.11 in its last earnings report, missing expectations of ₹17.3. Following the earnings report the stock price went up 1.928%.
Which hedge fund is a major shareholder of Glenmark Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLENMARK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Zydus Lifesciences Limited
―